查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1586057

癌症治疗和支持治疗药物市场：按癌症类型和药物类别划分－2025年至2030年全球预测

Cancer Therapeutics & Supportive Care Drugs Market by Cancer Type (Breast Cancer, Lung Cancer, Melanoma), Drug Class (Antiemetics, Bisphosphonates, Erythropoietin-Stimulating Agents) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年癌症治疗和支持治疗药物市值为3026.5亿美元，预计2024年将达到3343亿美元，复合年增长率为10.54%，到2030年将达到6107.2亿美元，预计将达到1000万美元。

癌症治疗和支持性护理药物市场的范围和定义包括各种旨在治疗癌症或减轻癌症治疗的症状和副作用的药物和治疗方法。该市场包括传统的细胞毒性药物、标靶治疗、免疫治疗以及止吐药和镇痛药等支持性治疗药物。这些药物的需求是由于全球各种类型癌症的盛行率不断增加，以及不仅针对癌细胞而且减轻治疗通讯协定副作用的综合治疗方案的需要。这些药物的应用范围和最终用途包括医院、癌症治疗中心、研究机构以及受益于居家照护解决方案的个别患者。

主要市场统计
基准年[2023] 3026.5亿美元
预测年份 [2024] 3343亿美元
预测年份 [2030] 6107.2亿美元
复合年增长率（%） 10.54%

影响市场成长的主要因素包括癌症发生率上升、促进个人化医疗市场开拓的生物技术进步以及全球医疗保健支出的增加。潜在的商机在于新兴市场、创新配方和有望提高疗效并减少副作用的联合治疗。为了利用这些机会，相关人员应该投资于研发，促进药物开发合作，并专注于个人化和精准医疗方法。

然而，市场开拓的挑战包括药物开发和癌症治疗相关的高成本、监管障碍以及一些癌症药物的副作用，这些副作用会导致患者的依从性问题。该领域的创新治疗将专注于改善药物传输系统，发现用于早期诊断和标靶治疗的新生物标记物，以及开发具有成本效益且可扩展的复杂生技药品。该市场是动态的，其特点是技术快速进步和主要参与者之间的激烈竞争。因此，永续成长需要对技术创新、监管理解和策略联盟的持续投资。为了克服挑战，企业必须灵活应对市场变化并开发以患者为中心的产品。

市场动态：快速发展的癌症药物和支持治疗药物市场的关键市场洞察

供需的动态交互作用正在改变癌症治疗和支持性护理药物市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助消费行为及其对製造业的影响。

  • 市场驱动因素
    • 癌症患者增加
    • 新药和治疗方法开发的创新
    • 对非侵入性治疗的需求不断增长
  • 市场限制因素
    • 抗癌药高成本
  • 市场机会
    • 癌症治疗持续创新
    • 生物相似药和生技药品的临床测试和开发
  • 市场挑战
    • 有限的兑换选项

波特五力：驾驭癌症药物和支持治疗药物市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解外部对癌症治疗和支持性护理药物市场的影响

外部宏观环境因素在塑造癌症治疗和支持性护理药物市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解癌症治疗和支持治疗药物市场的竞争状况

对癌症治疗和支持性护理药物市场的详细市场占有率分析提供了对供应商绩效的全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵癌症治疗和支持性护理药物市场供应商的绩效评估

FPNV 定位矩阵是评估癌症治疗和支持性护理市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议，描绘癌症治疗和支持性护理市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，癌症治疗和支持性护理药物市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 癌症患者发生率增加
      • 新药和治疗方法开发的创新
      • 对非侵入性治疗的需求不断增长
    • 抑制因素
      • 抗癌药物高成本
    • 机会
      • 癌症治疗的持续创新
      • 生物相似药和生物製药的临床测试和开发
    • 任务
      • 退款选项有限
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章按癌症类型分類的癌症治疗和支持治疗药物市场

  • 乳癌
  • 肺癌
  • 恶性黑色素瘤
  • 摄护腺癌

第 7 章：按药物类别分類的癌症治疗和支持治疗药物市场

  • 止吐药
  • 双磷酸盐
  • 促红血球生成素兴奋剂
  • 颗粒细胞增生因子
  • 非类固醇消炎剂
  • 阿片类药物

第八章北美和南美癌症治疗和支持治疗药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太地区癌症治疗及支持性治疗药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章欧洲、中东和非洲的癌症治疗和支持治疗药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Acacia Pharma Group PLC
  • Amgen Inc.
  • Aphios Corporation
  • AstraZeneca PLC
  • Bayer AG
  • Celldex Therapeutics
  • GSK PLC
  • Helsinn Healthcare SA
  • Heron Pharma
  • Ipsen Pharma
  • Johnson & Johnson
  • Merck & Co.
  • Novartis International AG
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-4316E4E89554

The Cancer Therapeutics & Supportive Care Drugs Market was valued at USD 302.65 billion in 2023, expected to reach USD 334.30 billion in 2024, and is projected to grow at a CAGR of 10.54%, to USD 610.72 billion by 2030.

The scope and definition of the cancer therapeutics and supportive care drugs market encompass a range of pharmaceutical products and therapies designed to treat cancer or alleviate the symptoms and side effects of cancer treatment. This market includes traditional cytotoxic drugs, targeted therapies, immunotherapies, and supportive care drugs like antiemetics and pain relievers. The necessity for these drugs stems from the increasing prevalence of various types of cancer globally and the need for comprehensive treatment options that not only target cancer cells but also mitigate the adverse effects of treatment protocols. The application and end-use scope of these drugs involves hospitals, cancer treatment centers, research institutes, and individual patients benefitting from home-based care solutions.

KEY MARKET STATISTICS
Base Year [2023] USD 302.65 billion
Estimated Year [2024] USD 334.30 billion
Forecast Year [2030] USD 610.72 billion
CAGR (%) 10.54%

Key factors influencing market growth include the rising incidence of cancer, advancements in biotechnology facilitating the development of personalized medicine, and increased healthcare spending globally. Potential opportunities lie in emerging markets, innovative drug formulations, and combination therapies that promise enhanced efficacy and reduced side effects. To capitalize on these opportunities, stakeholders should invest in R&D, foster collaborations for drug development, and focus on personalized and precision medicine approaches.

However, market growth is challenged by high costs associated with drug development and cancer treatment, regulatory hurdles, and the adverse effects of some cancer drugs, leading to patient compliance issues. Innovations in this sector could focus on improving drug delivery systems, discovering new biomarkers for earlier diagnosis and targeted treatment, and developing cost-effective and scalable production methods for complex biologics. The market is dynamic, characterized by rapid technological advancements and fierce competition among key players; thus, sustained growth necessitates continued investment in innovation, regulatory understanding, and strategic alliances. To navigate challenges, it is essential for businesses to remain agile, responsive to market changes, and committed to patient-centered product development.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cancer Therapeutics & Supportive Care Drugs Market

The Cancer Therapeutics & Supportive Care Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of cancer patients
    • Innovations in the development of new drugs and therapies
    • Growing demand for non-invasive therapies
  • Market Restraints
    • High cost of cancer drugs
  • Market Opportunities
    • Ongoing innovations for the treatment of cancer
    • Clinical trials and developments of biosimilars and biologics
  • Market Challenges
    • Limited reimbursement options

Porter's Five Forces: A Strategic Tool for Navigating the Cancer Therapeutics & Supportive Care Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cancer Therapeutics & Supportive Care Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cancer Therapeutics & Supportive Care Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cancer Therapeutics & Supportive Care Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cancer Therapeutics & Supportive Care Drugs Market

A detailed market share analysis in the Cancer Therapeutics & Supportive Care Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cancer Therapeutics & Supportive Care Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cancer Therapeutics & Supportive Care Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cancer Therapeutics & Supportive Care Drugs Market

A strategic analysis of the Cancer Therapeutics & Supportive Care Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cancer Therapeutics & Supportive Care Drugs Market, highlighting leading vendors and their innovative profiles. These include Acacia Pharma Group PLC, Amgen Inc., Aphios Corporation, AstraZeneca PLC, Bayer AG, Celldex Therapeutics, GSK PLC, Helsinn Healthcare SA, Heron Pharma, Ipsen Pharma, Johnson & Johnson, Merck & Co., Novartis International AG, Sanofi SA, Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Cancer Therapeutics & Supportive Care Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Cancer Type, market is studied across Breast Cancer, Lung Cancer, Melanoma, and Prostate Cancer.
  • Based on Drug Class, market is studied across Antiemetics, Bisphosphonates, Erythropoietin-Stimulating Agents, Granulocyte-Colony Stimulating Factors, Nonsteroidal Anti-Inflammatory Drugs, and Opioids.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of cancer patients
      • 5.1.1.2. Innovations in the development of new drugs and therapies
      • 5.1.1.3. Growing demand for non-invasive therapies
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of cancer drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing innovations for the treatment of cancer
      • 5.1.3.2. Clinical trials and developments of biosimilars and biologics
    • 5.1.4. Challenges
      • 5.1.4.1. Limited reimbursement options
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Cancer Therapeutics & Supportive Care Drugs Market, by Cancer Type

  • 6.1. Introduction
  • 6.2. Breast Cancer
  • 6.3. Lung Cancer
  • 6.4. Melanoma
  • 6.5. Prostate Cancer

7. Cancer Therapeutics & Supportive Care Drugs Market, by Drug Class

  • 7.1. Introduction
  • 7.2. Antiemetics
  • 7.3. Bisphosphonates
  • 7.4. Erythropoietin-Stimulating Agents
  • 7.5. Granulocyte-Colony Stimulating Factors
  • 7.6. Nonsteroidal Anti-Inflammatory Drugs
  • 7.7. Opioids

8. Americas Cancer Therapeutics & Supportive Care Drugs Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Cancer Therapeutics & Supportive Care Drugs Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Cancer Therapeutics & Supportive Care Drugs Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Acacia Pharma Group PLC
  • 2. Amgen Inc.
  • 3. Aphios Corporation
  • 4. AstraZeneca PLC
  • 5. Bayer AG
  • 6. Celldex Therapeutics
  • 7. GSK PLC
  • 8. Helsinn Healthcare SA
  • 9. Heron Pharma
  • 10. Ipsen Pharma
  • 11. Johnson & Johnson
  • 12. Merck & Co.
  • 13. Novartis International AG
  • 14. Sanofi SA
  • 15. Sun Pharmaceutical Industries Ltd.
  • 16. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY MELANOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANTIEMETICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY BISPHOSPHONATES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY ERYTHROPOIETIN-STIMULATING AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY GRANULOCYTE-COLONY STIMULATING FACTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY OPIOIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 24. BRAZIL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 26. CANADA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. CANADA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 28. MEXICO CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. MEXICO CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 30. UNITED STATES CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. UNITED STATES CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 32. UNITED STATES CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 33. ASIA-PACIFIC CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. ASIA-PACIFIC CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 35. ASIA-PACIFIC CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 36. AUSTRALIA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. AUSTRALIA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 38. CHINA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. CHINA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 40. INDIA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. INDIA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 42. INDONESIA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. INDONESIA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 44. JAPAN CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. JAPAN CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 46. MALAYSIA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. MALAYSIA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 48. PHILIPPINES CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. PHILIPPINES CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 50. SINGAPORE CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. SINGAPORE CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 52. SOUTH KOREA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. SOUTH KOREA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 54. TAIWAN CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. TAIWAN CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 56. THAILAND CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. THAILAND CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 58. VIETNAM CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. VIETNAM CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 60. EUROPE, MIDDLE EAST & AFRICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. EUROPE, MIDDLE EAST & AFRICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 62. EUROPE, MIDDLE EAST & AFRICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 63. DENMARK CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. DENMARK CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 65. EGYPT CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. EGYPT CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 67. FINLAND CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. FINLAND CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 69. FRANCE CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. FRANCE CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 71. GERMANY CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. GERMANY CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 73. ISRAEL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. ISRAEL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 75. ITALY CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. ITALY CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 77. NETHERLANDS CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. NETHERLANDS CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 79. NIGERIA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. NIGERIA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 81. NORWAY CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. NORWAY CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 83. POLAND CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. POLAND CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 85. QATAR CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. QATAR CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 87. RUSSIA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. RUSSIA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 89. SAUDI ARABIA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. SAUDI ARABIA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH AFRICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. SOUTH AFRICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 93. SPAIN CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. SPAIN CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 95. SWEDEN CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. SWEDEN CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 97. SWITZERLAND CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. SWITZERLAND CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 99. TURKEY CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. TURKEY CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED ARAB EMIRATES CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. UNITED ARAB EMIRATES CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 103. UNITED KINGDOM CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. UNITED KINGDOM CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 105. CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 106. CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET, FPNV POSITIONING MATRIX, 2023